TWD 58.3
(2.1%)
Year | Revenue | Revenue Growth |
---|---|---|
2023 | 7.15 Million TWD | -2.63% |
2022 | 7.35 Million TWD | -1.84% |
2021 | 7.48 Million TWD | 5.76% |
2020 | 7.08 Million TWD | 13.28% |
2019 | 6.25 Million TWD | 0.0% |
Year | Revenue | Revenue Growth |
---|---|---|
2024 Q2 | 1.63 Million TWD | 15.77% |
2024 Q1 | 1.4 Million TWD | -37.0% |
2023 Q1 | 1.54 Million TWD | -37.93% |
2023 Q4 | 2.23 Million TWD | 48.5% |
2023 Q3 | 1.5 Million TWD | -19.52% |
2023 Q2 | 1.87 Million TWD | 20.8% |
2022 Q4 | 2.49 Million TWD | 0.0% |
2022 FY | 7.35 Million TWD | -1.84% |
2021 FY | 7.48 Million TWD | 5.76% |
2020 FY | 7.08 Million TWD | 13.28% |
2019 FY | 6.25 Million TWD | 0.0% |
Name | Revenue | Revenue Difference |
---|---|---|
Apex Biotechnology Corp. | 1.67 Billion TWD | 99.573% |
Sinphar Pharmaceutical Co.,Ltd. | 2.96 Billion TWD | 99.758% |
Panion & Bf Biotech Inc. | 1.88 Billion TWD | 99.62% |
Chunghwa Chemical Synthesis & Biotech Co., Ltd. | 2.08 Billion TWD | 99.657% |
GenMont Biotech Incorporation | 318.01 Million TWD | 97.749% |
Abnova (Taiwan) Corporation | 382.05 Million TWD | 98.126% |
Adimmune Corporation | 1.78 Billion TWD | 99.599% |
Tanvex BioPharma, Inc. | 61.41 Million TWD | 88.344% |
Polaris Group | 7.48 Million TWD | 4.318% |
UnicoCell Biomed Co., Ltd. | 24.58 Million TWD | 70.889% |
PELL Bio-Med Technology Co. Ltd. | 18.03 Million TWD | 60.306% |